Goldman Sachs Group Inc Novavax Inc Put Options Transaction History

Goldman Sachs Group Inc

10 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q2 2024 Aug 13, 2024	BUY	$3.89 - $20.97 $5.18 Million - $27.9 Million	1,330,700 New	1,330,700 $16.8 Million
Q1 2023 May 14, 2024	BUY	$5.76 - $12.48 $2.54 Million - $5.51 Million	441,600 Added 881.44%	491,700 $3.41 Million
Q1 2023 May 11, 2023	BUY	$5.76 - $12.48 $2.54 Million - $5.51 Million	441,600 Added 881.44%	491,700 $3.41 Million
Q4 2022 May 14, 2024	SELL	$8.86 - $25.04 $2.03 Million - $5.73 Million	-228,700 Reduced 82.03%	50,100 $515,000
Q4 2022 Feb 13, 2023	SELL	$8.86 - $25.04 $2.03 Million - $5.73 Million	-228,700 Reduced 82.03%	50,100 $515,000
Q3 2022 May 14, 2024	BUY	$18.2 - $76.12 $3.23 Million - $13.5 Million	177,300 Added 174.68%	278,800 $5.07 Million
Q3 2022 Nov 10, 2022	BUY	$18.2 - $76.12 $3.23 Million - $13.5 Million	177,300 Added 174.68%	278,800 $5.07 Million
Q2 2022 May 14, 2024	BUY	$36.28 - $75.29 $3.68 Million - $7.64 Million	101,500 New	101,500 $5.22 Million
Q2 2022 Aug 15, 2022	SELL	$36.28 - $75.29 $2.81 Million - $5.83 Million	-77,400 Reduced 43.26%	101,500 $5.22 Million
Q4 2021 Feb 14, 2022	BUY	$134.56 - $217.97 $24.1 Million - $39 Million	178,900 New	178,900 $25.6 Million

291

93.4M

6.95M

9.4M

Ticker NVAX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,215,104
Market Cap $674M
Description
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; Nan...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.